Albuminuria as a surrogate marker for drug development: A European Regulatory perspective
- 1 November 2004
- journal article
- review article
- Published by Elsevier BV in Kidney International
- Vol. 66 (92), S126-S127
- https://doi.org/10.1111/j.1523-1755.2004.09232.x
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2001
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesThe New England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyThe New England Journal of Medicine, 2001
- Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic IndividualsJAMA, 2001
- Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive NephrosclerosisA Randomized Controlled TrialJAMA, 2001
- Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease.JAMA, 1999
- Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?JAMA, 1999
- Pathophysiology of Progressive NephropathiesThe New England Journal of Medicine, 1998
- Understanding the nature of renal disease progressionKidney International, 1997
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996